<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-5552</journal-id>
<journal-title><![CDATA[Revista Salud Uninorte]]></journal-title>
<abbrev-journal-title><![CDATA[Salud, Barranquilla]]></abbrev-journal-title>
<issn>0120-5552</issn>
<publisher>
<publisher-name><![CDATA[Fundación Universidad del Norte, División de Ciencias de la]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-55522018000300607</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Epidemiologia de la hipertensión pulmonar en Colombia]]></article-title>
<article-title xml:lang="en"><![CDATA[Epidemiology of pulmonary hypertension in Colombia]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Miranda M]]></surname>
<given-names><![CDATA[Pablo A.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Guzmán Sáenz]]></surname>
<given-names><![CDATA[Roberto C.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Baños A]]></surname>
<given-names><![CDATA[Ivan]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alvarez B]]></surname>
<given-names><![CDATA[Álvaro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Nacional de Colombia  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad del Norte  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad Nacional de Colombia  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Universidad de Cartagena  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2018</year>
</pub-date>
<volume>34</volume>
<numero>3</numero>
<fpage>607</fpage>
<lpage>624</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-55522018000300607&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-55522018000300607&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-55522018000300607&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo: Estimar la prevalência e incidencia de la hipertensión pulmonar (HTP) en Colombia entre el periodo comprendido entre 2010 y 2014.  Metodologia: Estudio de corte transversal utilizando la Bodega de Datos del Sistema Integral de Información de la Protección Social (SISPRO) del Ministerio de Salud y Protección Social (MSPS). Se incluyeron todas las personas atendidas a nivel nacional que tenían registrado los diagnósticos de Hipertensión Pulmonar Primaria (Clasificación Internacional de Enfermedades CIE-101270), durante el periodo establecido para el estudio.  Resultados: Se estimó que la prevalencia e incidencia de HTP es de aproximadamente 52 y 20 casos por cada millón de habitantes, respectivamente. Predomina en el sexo femenino y en los grupos de edad mayores de 60 años.  Conclusión: Las estimaciones epidemiológicas de la HTP en Colombia son compatibles con la definición de enfermedades huérfanas o raras.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective: To estimate the prevalence and incidence of pulmonary hypertension (PH) in Colombia between the period between 2010 and 2014.  Methodology: Cross-sectional study using the Data Warehouse of the Social Protection Information System (SISPRO) of the Ministry of Health and Social Protection (MSPS). We included all the nationwide patients who had registered the diagnoses of Primary Pulmonary Hypertension (ICD-101270) during the period established for the study.  Results: It was estimated that the prevalence and incidence of PH is approximately 52 and 20 cases per million inhabitants, respectively. It predominates in the female sex and in the age groups over 60 years.  Conclusion: Epidemiological estimates of PH in Colombia are consistent with the definition of orphan or rare diseases.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[hipertensión pulmonar]]></kwd>
<kwd lng="es"><![CDATA[prevalencia]]></kwd>
<kwd lng="es"><![CDATA[incidencia]]></kwd>
<kwd lng="es"><![CDATA[epidemiologia]]></kwd>
<kwd lng="en"><![CDATA[pulmonary hypertension]]></kwd>
<kwd lng="en"><![CDATA[prevalence]]></kwd>
<kwd lng="en"><![CDATA[incidence]]></kwd>
<kwd lng="en"><![CDATA[epidemiology]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Firth]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Mandel]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Yuan]]></surname>
<given-names><![CDATA[JX]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Idiopathic pulmonary arterial hypertension]]></article-title>
<source><![CDATA[Disease models &amp; mechanisms]]></source>
<year>2010</year>
<volume>3</volume>
<page-range>5-6</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<source><![CDATA[!!! INVALID CITATION !!!]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dunlap]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Weyer]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pulmonary Hypertension: Diagnosis and Treatment]]></article-title>
<source><![CDATA[American family physician]]></source>
<year>2016</year>
<volume>94</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>463-9</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hoeper]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Bogaard]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Condliffe]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Frantz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Khanna]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Kurzyna]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Definitions and diagnosis of pulmonary hypertension]]></article-title>
<source><![CDATA[Journal of the American College of Cardiology]]></source>
<year>2013</year>
<volume>62</volume>
<numero>25</numero>
<issue>25</issue>
<page-range>D42-50</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dutta]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Aronow]]></surname>
<given-names><![CDATA[WS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Echocardiographic evaluation of the right ventricle]]></article-title>
<source><![CDATA[Clinical implications]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Waligora]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kopec]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Jonas]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Tyrka]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sarnecka]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Miszalski-Jamka]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mechanism and prognostic role of qR in V1 in patients with pulmonary arterial hypertension]]></article-title>
<source><![CDATA[Journal of electrocardiology]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barbera]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Blanco]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of Pulmonary Hypertension in Patients with Chronic Lung Disease]]></article-title>
<source><![CDATA[Current hypertension reports]]></source>
<year>2015</year>
<volume>17</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>62</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morris]]></surname>
<given-names><![CDATA[NR]]></given-names>
</name>
<name>
<surname><![CDATA[Kermeen]]></surname>
<given-names><![CDATA[FD]]></given-names>
</name>
<name>
<surname><![CDATA[Holland]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Exercise-based rehabilitation programmes for pulmonary hypertension]]></article-title>
<source><![CDATA[The Cochrane database of systematic reviews]]></source>
<year>2017</year>
<volume>1</volume>
<page-range>Cd011285</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beltran-Gamez]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Sandoval-Zarate]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pulido]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension]]></article-title>
<source><![CDATA[Archivos de cardiologia de Mexico]]></source>
<year>2015</year>
<volume>85</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>215-24</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Olschewski]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Simonneau]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Galie]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Hi-genbottam]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Naeije]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rubin]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inhaled iloprost for severe pulmonary hypertension]]></article-title>
<source><![CDATA[The New England journal of medicine]]></source>
<year>2002</year>
<volume>347</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>322-9</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rubin]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Badesch]]></surname>
<given-names><![CDATA[DB]]></given-names>
</name>
<name>
<surname><![CDATA[Barst]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Galie]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Black]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Keogh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bosentan therapy for pulmonary arterial hypertension]]></article-title>
<source><![CDATA[The New England journal of medicine]]></source>
<year>2002</year>
<volume>346</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>896-903</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fan]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Calcium channel bloc-kers for pulmonary arterial hypertension]]></article-title>
<source><![CDATA[The Cochrane database of systematic reviews]]></source>
<year>2015</year>
<numero>9</numero>
<issue>9</issue>
<page-range>Cd010066</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ghofrani]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
<name>
<surname><![CDATA[Galie]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Grimminger]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Grunig]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Humbert]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Jing]]></surname>
<given-names><![CDATA[ZC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Riociguat for the treatment of pulmonary arterial hypertension]]></article-title>
<source><![CDATA[The New England journal of medicine]]></source>
<year>2013</year>
<volume>369</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>330-40</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rubin]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of pulmonary hypertension caused by left heart failure with pulmonary arterial hypertension-specific therapies: lessons from the right and LEPHT]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2013</year>
<volume>128</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>475-6</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caldeira]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Loureiro]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pinto]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oral anticoagulation for pulmonary arterial hypertension: systematic review and meta-analysis]]></article-title>
<source><![CDATA[The Canadian journal of cardiology]]></source>
<year>2014</year>
<volume>30</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>879-87</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dranitsaris]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Mehta]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis]]></article-title>
<source><![CDATA[Applied health economics and health policy]]></source>
<year>2009</year>
<volume>7</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>43-59</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lugones Botell]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez Bermúdez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enfermedades raras]]></article-title>
<source><![CDATA[Revista Cubana de Medicina General Integral]]></source>
<year>2012</year>
<volume>28</volume>
<page-range>340</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moreo]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Lattimer]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lett]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Heggen-Peay]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Simone]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Integrated Transitions of Care for Patients With Rare Pulmonary Diseases]]></article-title>
<source><![CDATA[Professional case management]]></source>
<year>2017</year>
<volume>22</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>54-63</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mocumbi]]></surname>
<given-names><![CDATA[AO]]></given-names>
</name>
<name>
<surname><![CDATA[Thienemann]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Sliwa]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A global perspective on the epidemiology of pulmonary hypertension]]></article-title>
<source><![CDATA[The Canadian journal of cardiology]]></source>
<year>2015</year>
<volume>31</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>375-81</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Escribano Subias]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Barberà Mir]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Suberviola]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluación diagnóstica y pronóstica actual de la hipertensión pulmonar]]></article-title>
<source><![CDATA[Revista Española de Cardiología]]></source>
<year>2010</year>
<volume>63</volume>
<numero>05</numero>
<issue>05</issue>
<page-range>583-96</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vaid]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Camacho]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Granton]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Mamdani]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Yao]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Characteristics of Treated Pulmonary Arterial Hypertension Patients in Ontario]]></article-title>
<source><![CDATA[Canadian respiratory journal]]></source>
<year>2016</year>
<volume>2016</volume>
<page-range>627-9250</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thenappan]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ryan]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Archer]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evolving epidemiology of pulmonary arterial hypertension]]></article-title>
<source><![CDATA[American journal of respiratory and critical care medicine]]></source>
<year>2012</year>
<volume>186</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>707-9</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="">
<collab>Salud IdEdTe</collab>
<source><![CDATA[Análisis de impacto presu-puestal de las terapias combinadas bosen-tan + sildenafil, ambrisentan + tadalafil e iloprost + bosentan en pacientes diagnosticados con hipertensión pulmonar grupo 1 (HAPG1 idiopática-HAPI y asociada-HAPA) de clase funcional II, III y IV de la NYHA/ WHO en Colombia. Instituto de Evaluación de Tecnologias en Salud (IETS)]]></source>
<year>2016</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
